Loading company…
RayGene Pharmaceutics develops drugs and targeted delivery systems, with a focus on liver tumors.
Founded in 2019 and based in Shaoxing, China, RayGene Pharmaceutics develops drugs for liver tumors and targeted delivery systems. Its pipeline includes ida001 for Parkinson's disease and engineered natural killer cell programs. The company closed funding from Lapam Capital in November 2024 and from Synthetic Vaccine Biotech in August 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in